Clinical trials: Adjuvant Therapy
Breast Cancer
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00895414
- Testing
- doxorubicin hydrochloride, enalapril maleate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Pneumonia, Bacterial
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and…
- Trial name
- INHALE 1 (NCT01799993)
- Testing
- Amikacin Inhalation Solution (BAY41-6551)
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 725 people
- Sponsor
- Bayer
Differentiated Thyroid Cancer
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.
- Trial name
- ASTRA (NCT01843062)
- Testing
- Selumetinib, Radioactive Iodine Therapy
- Where
- 45 sites in United States, Brazil and 6 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca
Breast Neoplasms
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
The general aim of this study is to investigate the efficacy and safety of afatinib (BIBW 2992) alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who progress on afatinib monotherapy within this…
- Trial name
- NCT01271725
- Testing
- Vinorelbine 25 mg/m2 weekly, Afatinib 40mg once daily (OD), Paclitaxel 80 mg/m2 weekly
- Where
- 27 sites in Hong Kong, India and 4 more
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
The primary objective was to estimate the tolerability and safety of 2 doses of teriflunomide administered once daily for 24 weeks, compared with placebo, in patients with multiple sclerosis [MS] with relapses who were on a…
- Trial name
- NCT00489489
- Testing
- Teriflunomide, Interferon-β
- Where
- 5 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Sanofi
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
This phase II trial studies how well dabrafenib, trametinib, and spartalizumab works in treating patients with BRAF V600E or V600K mutation positive stage IIIB/C/D melanoma, who do not achieve a pathologic complete response after…
- Conditions
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT04310397
- Testing
- Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed by single agent erlotinib for a total of 12…
- Trial name
- NCT00336700
- Testing
- Gemcitabine, Erlotinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert J. Zeh, III MD, FACS
Epilepsy
P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.
In up to 1 out of 3 patients with epilepsy, seizures continue to occur despite the use of one or more antiepileptic medications.
- Trial name
- NCT00524134
- Testing
- Carvedilol-CR
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Seizures
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
The goal of this clinical trial is to learn if CVL-865, when taken regularly with other anti-seizure medicines, works to prevent seizures in adults with drug-resistant focal onset seizures.
- Trial name
- NCT04244175
- Testing
- CVL-865
- Where
- 76 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Breast Cancer
Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)
Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2.
- Trial name
- OTT15-04 (NCT02688803)
- Testing
- Dose dense AC-P, Dose dense AC, FEC-D
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ottawa Hospital Research Institute
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery.
- Conditions
- Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma
- Trial name
- NCT01958580
- Testing
- Gemcitabine Hydrochloride, Docetaxel, Internal Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Albert Einstein College of Medicine
Focal Onset Seizures
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are…
- Trial name
- NCT04836559
- Testing
- JNJ-40411813
- Where
- 69 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Malignant Glioma, Recurrent Glioblastoma
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient's immune system attack their tumor (glioblastoma multiforme - GBM).
- Trial name
- NCT02794883
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Surgical Procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
Post-Traumatic Headache
Dexamethasone for Post Traumatic Headache
This is a randomized study of intravenous metoclopramide + intravenous dexamethasone versus intravenous metoclopramide for patients with acute post-traumatic headache.
- Trial name
- NCT04799015
- Testing
- Dexamethasone, Metoclopramide 10mg
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Montefiore Medical Center
Alzheimer's Disease
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind…
- Trial name
- NCT01238991
- Testing
- ACC-001
- Where
- 11 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Pfizer
Epilepsy
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures
The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.
- Trial name
- NCT01191086
- Testing
- USL255
- Where
- 68 sites in United States, Argentina and 13 more
- Volunteers
- 210 people
- Sponsor
- Upsher-Smith Laboratories
Breast Cancer
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer.
- Trial name
- NCT00127205
- Testing
- clodronate disodium, ibandronate sodium, zoledronic acid
- Volunteers
- 6,097 people
- Sponsor
- SWOG Cancer Research Network
Epilepsy With Partial-onset Seizures
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
The purpose of this trial is to assess the efficacy, safety and tolerability of lacosamide administered as add-on therapy with 1 to 3 anti-seizure medications.
- Trial name
- NCT02477839
- Testing
- Lacosamide
- Where
- 88 sites in United States, Argentina and 24 more
- Volunteers
- 255 people
- Sponsor
- UCB BIOSCIENCES, Inc.